---
title: "Pfizer filed a lawsuit aimed at blocking Novo Nordisk's acquisition of the obesity drug company Metsera"
description: "Pfizer has filed a lawsuit against Metsera Inc. and Novo Nordisk AS, aiming to block Novo Nordisk's acquisition of Metsera. Pfizer is requesting the Delaware court in the United States to halt the tra"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263813901.md"
published_at: "2025-10-31T22:32:13.000Z"
---

# Pfizer filed a lawsuit aimed at blocking Novo Nordisk's acquisition of the obesity drug company Metsera

> Pfizer has filed a lawsuit against Metsera Inc. and Novo Nordisk AS, aiming to block Novo Nordisk's acquisition of Metsera. Pfizer is requesting the Delaware court in the United States to halt the transaction in order to obtain a hearing. Pfizer believes that Novo Nordisk's offer does not meet the criteria for a "superior company proposal." Meanwhile, U.S. antitrust enforcement agencies have approved Pfizer to continue pursuing its acquisition offer for Metsera

Pfizer has sued Metsera Inc. and Novo Nordisk AS, seeking to block Novo Nordisk's competitive acquisition of this emerging obesity drug company. Pfizer is requesting the Delaware Chancery Court to prevent Metsera from completing the transaction with Novo Nordisk, allowing Pfizer time to obtain a hearing. Pfizer stated that under the merger agreement, Novo Nordisk's offer does not meet the criteria for a "Superior Company Proposal." Pfizer announced that U.S. antitrust enforcement agencies have approved its continued pursuit of the acquisition offer for Metsera, stating that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act has ended, "satisfying the regulatory review requirements for the proposed acquisition."

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J 在諾和諾德公司 $NVO 擁有價值 32 萬美元的股票持倉 | Puzo Michael J 在第三季度大幅減持了 Novo Nordisk A/S (NYSE:NVO) 的股份，減少幅度達到 86.9%，目前持有 5,775 股，價值 320,000 美元。其他機構投資者也調整了他們的持倉，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 諾和諾德公司提議任命兩名新的董事會成員 | 丹麥製藥公司諾和諾德公司提議在 3 月 26 日於哥本哈根舉行的年度股東大會上新增三名董事會成員。提議的成員包括海倫娜·薩克森、揚·範·德·温克爾和拉莫娜·塞奎拉。薩克森此前已宣佈辭去 Sobi 的職務以加入諾和諾德。還提議重新選舉董事長拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| GLP-1 抗肥胖藥物在美國市場的四張圖表 | 瑞士銀行的分析師們在馬修·韋斯頓的帶領下，分析了美國 GLP-1 抗肥胖藥物市場的趨勢，重點關注 Wegovy 的新品牌處方（NBRx）。數據顯示，Wegovy 的新品牌處方趨勢強勁，新推出的 Wegovy 藥丸對其影響甚微。即將發生的關鍵 | [Link](https://longbridge.com/en/news/276280378.md) |
| 諾和諾德公司 - 股份回購計劃 | 諾和諾德公司已啓動一項最高達 150 億丹麥克朗的股票回購計劃，計劃於 2026 年 2 月 4 日開始。截至 2026 年 2 月 13 日，公司已回購 1,750,000 股 B 類股票，平均價格為 305.03 丹麥克朗，總計為 53 | [Link](https://longbridge.com/en/news/276056741.md) |
| 諾和諾德公司董事會提議再次選舉 Lars Rebien Sorensen 擔任主席 | 諾和諾德公司董事會提議重新選舉拉斯·瑞比恩·索倫森為董事長 | [Link](https://longbridge.com/en/news/276440991.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.